Treatment outcomes of IMEP as a front-line chemotherapy for patients with peripheral T-cell lymphomas.
- Author:
Ji Young LEE
1
;
Sang Min LEE
;
Moon Young CHOI
;
Ki Hyang KIM
;
Young Don JOO
;
Sung Nam IM
;
Won Sik LEE
Author Information
- Publication Type:Original Article
- Keywords: Peripheral T-cell lymphomas; IMEP; Ifosphamide; Etoposide; Prednisolone
- MeSH: Busan; Disease-Free Survival; Drug Therapy*; Etoposide; Follow-Up Studies; Humans; Lymphoma, T-Cell, Peripheral*; Mesna; Mortality; Neutropenia; Prednisolone; Retrospective Studies; Survival Rate; Thrombocytopenia
- From:Blood Research 2016;51(3):187-192
- CountryRepublic of Korea
- Language:English
- Abstract: BACKGROUND: This study aimed to assess the treatment outcomes of ifosphamide, mesna, etoposide, and prednisolone (IMEP) combination regimen as a front-line chemotherapy in patients with peripheral T-cell lymphomas (PTCLs). METHODS: Clinical data of 38 newly diagnosed PTCLs patients who underwent IMEP at Busan Paik Hospital from January 2002 to December 2013 were retrospectively analyzed. RESULTS: The overall response rate was 68.5%, with 21 (55.3%) complete response/complete response unconfirmed and 6 (15.8%) partial response (PR). The median follow-up duration was 25.5 months (range, 0.2-87.3). The median overall survival was not reached and 2-year survival rate was 67%. The median progression free survival was 23 months. The most frequently reported adverse effects higher than grade 3 were hematologic toxicities including neutropenia (68.4%), thrombocytopenia (42.1%). There was no treatment-related mortality. CONCLUSION: IMEP regimen is effective and safe as a front-line chemotherapy in patients with PTCLs.
